H.C. Wainwright analyst Yi Chen raised the firm’s price target on Mainz Biomed to $9 from $7 and keeps a Buy rating on the shares. The company last week announced positive results from the European ColoFuture study assessing the potential to integrate a portfolio of novel gene expression biomarkers into the company’s stool-based ColoAlert test for the detection of colorectal cancer, the analyst tells investors in a research note. The firm says the results are “highly promising” as the integration of biomarkers not only improves the sensitivity and specificity for CRC detection, but enables the identification of advance adenoma at 81% sensitivity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed announces topline results from ColoFuture study
- Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
- Mainz Biomed enters pact with Arztliches Labor Dr. Buhlmann in Germany
- Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
- Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference